FGP
CNMD icon

Freestone Grove Partners’s CONMED CNMD Stock Holding History

Freestone Grove Partners’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.3K Sell
1,027
-10,190
-91% -$415K ﹤0.01% 847
2025
Q4 		$455K Buy
+11,217
New +$488K ﹤0.01% 587

Other funds holding CNMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

Freestone Grove Partners's CNMD Position: Q1 2026 in Review

Freestone Grove Partners reduced its CONMED (CNMD) stake by 91% in Q1 2026, selling an estimated $415K and leaving 1,027 shares worth $36.3K. The position accounts for ﹤0.01% of the portfolio, ranked #847.

Freestone Grove Partners first reported a position in CNMD in Q4 2025 and has held it in 2 quarters since. The position peaked at $455K in Q4 2025. 236 funds tracked by Wall St. Rank hold CNMD as of Q1 2026.

  • Freestone Grove Partners held 1,027 shares of CONMED worth $36.3K as of Q1 2026.
  • Freestone Grove Partners sold 10,190 CONMED shares in Q1 2026, an estimated $415K.
  • CONMED made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #847 holding.
  • Freestone Grove Partners first reported a position in CONMED in Q4 2025 and has held it in 2 quarters since.
  • Freestone Grove Partners's CONMED position peaked at $455K in Q4 2025.
  • 236 funds tracked by Wall St. Rank held CONMED as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.